203 related articles for article (PubMed ID: 23253691)
1. Short and long-term quality of life and asthma control with omalizumab therapy in a real life setting in Portugal.
Vieira T; de Oliveira JF; da Graça Castel-Branco M
Allergol Immunopathol (Madr); 2014; 42(1):3-10. PubMed ID: 23253691
[TBL] [Abstract][Full Text] [Related]
2. Effect of omalizumab as add-on therapy on asthma-related quality of life in severe allergic asthma: a Brazilian study (QUALITX).
Rubin AS; Souza-Machado A; Andradre-Lima M; Ferreira F; Honda A; Matozo TM;
J Asthma; 2012 Apr; 49(3):288-93. PubMed ID: 22356355
[TBL] [Abstract][Full Text] [Related]
3. Assessment of long-term omalizumab treatment in patients with severe allergic asthma long-term omalizumab treatment in severe asthma.
Özgür ES; Özge C; Ïlvan A; Naycı SA
J Asthma; 2013 Aug; 50(6):687-94. PubMed ID: 23557459
[TBL] [Abstract][Full Text] [Related]
4. Long-term omalizumab treatment in severe allergic asthma: the South-Eastern Mediterranean "real-life" experience.
Tzortzaki EG; Georgiou A; Kampas D; Lemessios M; Markatos M; Adamidi T; Samara K; Skoula G; Damianaki A; Schiza S; Tzanakis N; Siafakas NM
Pulm Pharmacol Ther; 2012 Feb; 25(1):77-82. PubMed ID: 22155001
[TBL] [Abstract][Full Text] [Related]
5. The real-life clinical effects of 52 weeks of omalizumab therapy for severe persistent allergic asthma.
Gouder C; West LM; Montefort S
Int J Clin Pharm; 2015 Feb; 37(1):36-43. PubMed ID: 25394832
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR.
Vignola AM; Humbert M; Bousquet J; Boulet LP; Hedgecock S; Blogg M; Fox H; Surrey K
Allergy; 2004 Jul; 59(7):709-17. PubMed ID: 15180757
[TBL] [Abstract][Full Text] [Related]
7. Omalizumab reduces corticosteroid use in patients with severe allergic asthma: real-life experience in Israel.
Rottem M
J Asthma; 2012 Feb; 49(1):78-82. PubMed ID: 22149205
[TBL] [Abstract][Full Text] [Related]
8. "Real-life" effectiveness of omalizumab in patients with severe persistent allergic asthma: The PERSIST study.
Brusselle G; Michils A; Louis R; Dupont L; Van de Maele B; Delobbe A; Pilette C; Lee CS; Gurdain S; Vancayzeele S; Lecomte P; Hermans C; MacDonald K; Song M; Abraham I
Respir Med; 2009 Nov; 103(11):1633-42. PubMed ID: 19619998
[TBL] [Abstract][Full Text] [Related]
9. Add-on omalizumab in children with severe allergic asthma: a 1-year real life survey.
Deschildre A; Marguet C; Salleron J; Pin I; Rittié JL; Derelle J; Taam RA; Fayon M; Brouard J; Dubus JC; Siret D; Weiss L; Pouessel G; Beghin L; Just J
Eur Respir J; 2013 Nov; 42(5):1224-33. PubMed ID: 23520319
[TBL] [Abstract][Full Text] [Related]
10. A 36-month study on the cost/utility of add-on omalizumab in persistent difficult-to-treat atopic asthma in Italy.
Dal Negro RW; Tognella S; Pradelli L
J Asthma; 2012 Oct; 49(8):843-8. PubMed ID: 22954018
[TBL] [Abstract][Full Text] [Related]
11. Modeling the effects of omalizumab over 5 years among patients with moderate-to-severe persistent allergic asthma.
Grossman HL; Schlender A; Alperin P; Stanley EL; Zhang J
Curr Med Res Opin; 2010 Dec; 26(12):2779-93. PubMed ID: 21050061
[TBL] [Abstract][Full Text] [Related]
12. [Omalizumab therapy in adolescents with severe allergic asthma - results of a post-marketing surveillance].
Klyucheva M; von Berg A; Gappa M; Suerbaum C; Berdel D
Pneumologie; 2013 Apr; 67(4):233-7. PubMed ID: 23576201
[TBL] [Abstract][Full Text] [Related]
13. Clinical and pharmacoeconomic aspects of omalizumab: a 4-year follow-up.
Menzella F; Facciolongo N; Piro R; Formisano D; Roggeri A; Simonazzi A; Castagnetti C; Carbonelli C; Zucchi L
Ther Adv Respir Dis; 2012 Apr; 6(2):87-95. PubMed ID: 22323442
[TBL] [Abstract][Full Text] [Related]
14. Omalizumab in patients with severe asthma: the XCLUSIVE study.
Schumann C; Kropf C; Wibmer T; Rüdiger S; Stoiber KM; Thielen A; Rottbauer W; Kroegel C
Clin Respir J; 2012 Oct; 6(4):215-27. PubMed ID: 21740532
[TBL] [Abstract][Full Text] [Related]
15. Incidence of malignancy in patients with moderate-to-severe asthma treated with or without omalizumab.
Long A; Rahmaoui A; Rothman KJ; Guinan E; Eisner M; Bradley MS; Iribarren C; Chen H; Carrigan G; Rosén K; Szefler SJ
J Allergy Clin Immunol; 2014 Sep; 134(3):560-567.e4. PubMed ID: 24679845
[TBL] [Abstract][Full Text] [Related]
16. Omalizumab therapy in severe asthma: experience from the Spanish registry--some new approaches.
Vennera Mdel C; Pérez De Llano L; Bardagí S; Ausin P; Sanjuas C; González H; Gullón JA; Martínez-Moragón E; Carretero JA; Vera E; Medina JF; Alvarez FJ; Entrenas LM; Padilla A; Irigaray R; Picado C;
J Asthma; 2012 May; 49(4):416-22. PubMed ID: 22443408
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma.
Holgate ST; Chuchalin AG; Hébert J; Lötvall J; Persson GB; Chung KF; Bousquet J; Kerstjens HA; Fox H; Thirlwell J; Cioppa GD;
Clin Exp Allergy; 2004 Apr; 34(4):632-8. PubMed ID: 15080818
[TBL] [Abstract][Full Text] [Related]
18. A 26-week, randomized, double-blind, placebo-controlled, multicenter study to evaluate the effect of omalizumab on asthma control in patients with persistent allergic asthma.
Bardelas J; Figliomeni M; Kianifard F; Meng X
J Asthma; 2012 Mar; 49(2):144-52. PubMed ID: 22277052
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of omalizumab in patients with inadequately controlled severe persistent allergic asthma: an open-label study.
Niven R; Chung KF; Panahloo Z; Blogg M; Ayre G
Respir Med; 2008 Oct; 102(10):1371-8. PubMed ID: 18657960
[TBL] [Abstract][Full Text] [Related]
20. Omalizumab is effective in the long-term control of severe allergic asthma.
Lanier BQ; Corren J; Lumry W; Liu J; Fowler-Taylor A; Gupta N
Ann Allergy Asthma Immunol; 2003 Aug; 91(2):154-9. PubMed ID: 12952109
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]